CD33 and acute myeloid leukemia: In NSG mice model of AML xenotransplantation, a novel second-generation anti-CD33 CAR that incorporates a 4-1BB-CD3ζ signaling tail, CD 33 CART can significantly reduce tumor load and prolong survival time (112).